Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarker sbp1 for early diagnosis of renal diseases, and use thereof

A technology for early diagnosis of kidney disease, applied in the field of biomarker composition, selenium binding protein 1, can solve the problems of missing the best time to treat renal dysfunction, and achieve high sensitivity and specificity

Pending Publication Date: 2019-06-14
SERGENTECH GMBH
View PDF6 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in reality, when renal dysfunction occurs, serum Cr increases after considerable progression of renal dysfunction, so when diagnosing acute / chronic renal failure, the best time to treat renal dysfunction is often missed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarker sbp1 for early diagnosis of renal diseases, and use thereof
  • Biomarker sbp1 for early diagnosis of renal diseases, and use thereof
  • Biomarker sbp1 for early diagnosis of renal diseases, and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0106] Example 1. Experimental Animals and Methods

[0107] Using male SD rats (6 weeks old, male Sprague-Dawley rats) purchased from Charles River Laboratories (Orient, Seoul, Korea), experiments were performed in accordance with the guidelines of the Experimental Animal Testing and Research Ethics Committee of Sungkyunkwan University .

[0108] 1-1. Preparation of animal model of diabetes

[0109] In one embodiment of the present invention, a diabetic animal model administered with STZ and a diabetic model using Zucker diabetic fat (ZDF) rats were prepared as diabetic animal models.

[0110] First, as a STZ-administered diabetic animal model, a single dose of STZ (50 mg / kg) was administered intraperitoneally (I.P.) to Sprague-Dawley rats (white), and blood glucose levels were measured daily to assess whether the blood glucose levels were increased sufficiently to confirm The incidence of diabetes was increased (approximately 5-fold increase), and here, some experimental gr...

Embodiment 2

[0124] Example 2. Validation of animal models of diabetes and renal failure

[0125] 2-1. Validation of the model with STZ-induced diabetes

[0126] In order to verify the animal model of diabetes induced by the administration of STZ according to Example 1-1 of the present invention, by designing Figure 1A Experiments were carried out on the experimental model described above.

[0127] results, such as Figure 1B and 1C As shown, in the control, a normal blood sugar level was shown, but in the STZ-administered animal group, the blood sugar level was increased by about 6 times or more (600 mg / dL or more) compared to the control. However, in the experimental group of diabetic animals treated with antidiabetic drugs, it was confirmed that the blood sugar level gradually decreased on the 7th, 14th and 21st days, and almost decreased to the normal level on the last day (28th day). In addition, by measuring microalbumin in urine, which is one of the most important factors of dia...

Embodiment 3

[0145] Example 3. Problems using conventional markers for renal dysfunction

[0146] According to this Example of the present invention, it was confirmed whether the type II diabetic renal failure animal model has renal failure due to diabetes, as clinically indicated. As a result, it was demonstrated that both types (type I and type II) of the diabetes model have renal dysfunction. Thus, it was confirmed that BUN, creatinine, and microalbumin, which are markers for diagnosing renal function, were significantly detected in diabetic rats.

[0147] In addition, in routine tests for the diagnosis of renal dysfunction, cisplatin / HgCl is diagnosed by measuring representative markers 2 The representative markers such as serum creatinine (SCr), BUN and glucose contained in the urine, LDH, aspartate aminotransferase (AST) and total protein.

[0148] 3-1. Confirm that heavy metals (mercury, HgCl 2 ) induced chronic renal dysfunction

[0149] Subsequently, after oral administration ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A biomarker and a technology for utilizing the same, of the present invention, can be useful in the early diagnosis, in urine, of a renal function abnormality due to diabetes and drugs and in the prediction and evaluation of disease severity, and, further, can accurately determine, with high sensitivity and specificity, a renal function abnormality due to diabetes and exposure to drugs, and enablethe early and effective diagnosis of kidney abnormality symptoms through a relatively simple method, thereby being widely usable in various fields, such as in clinical experiments essential for new drug development and in diagnosing drug-causing acute / chronic renal failure, which can frequently occur in the clinical treatment process.

Description

technical field [0001] The present invention relates to a biomarker for early diagnosis of kidney disease and application thereof, the biomarker is selenium binding protein 1 (SBP1). More specifically, the present invention relates to a composition for detecting biomarkers for early diagnosis of kidney disease, a kit containing the composition, an animal test method and a clinical test method using the kit, and a detection method thereof. Background technique [0002] The kidney is an organ that excretes various substances that are metabolized in the body and are therefore present in the blood, especially filtering the blood through glomerular filtration and renal tubular absorption and reabsorption, thereby excreting unnecessary waste from the body in the form of urine organs. The kidneys weigh only about 0.5 percent of body weight, but the volume of blood flowing into the kidneys is 20 to 25 percent of the total cardiac output. Therefore, the kidney is one of the most vu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883G01N33/68
CPCC12Q1/68G01N33/6893G01N2800/347C12Q1/6883G01N2333/46C12Q2600/158G01N33/68
Inventor 李秉武金衡植金勍奭孙知延
Owner SERGENTECH GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com